Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...
Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...
GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options ...
The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...
PERSPECTIVES: The resurgence of Y2K skin-baring fashion trends coincides with the rise of prescription weight loss drugs like ...
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.
Shares in Novo Nordisk have fallen by more than a quarter after the Ozempic maker revealed a set of underwhelming results in ...
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
The company behind KitKat has launched a protein drink that it claims suppresses appetite in the same way as popular ...
SHOPPING: If you're ready to meet your weight goals, turn to Hims for personalized weight loss treatments that are ...
But semaglutide – sold as Ozempic and Wegovy – has been linked to a rare ... SGLT-2is. In Norway, the same research found an even starker difference – 2.9 in 10,000, compared with 0.92.